Cargando…

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults

BACKGROUND: Clostridioides difficile infection (CDI) rates have plateaued at historical highs in the United States since 2010 and remains a major health problem. While optimal CDI testing remains unclear, current literature recommends testing patients whose symptoms are not clinically attributable t...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Bahou, Amanda, Quilitz, Rod, Pasikhova, Yanina, Greene, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644424/
http://dx.doi.org/10.1093/ofid/ofab466.952
_version_ 1784610082240069632
author Al-Bahou, Amanda
Quilitz, Rod
Pasikhova, Yanina
Greene, John
author_facet Al-Bahou, Amanda
Quilitz, Rod
Pasikhova, Yanina
Greene, John
author_sort Al-Bahou, Amanda
collection PubMed
description BACKGROUND: Clostridioides difficile infection (CDI) rates have plateaued at historical highs in the United States since 2010 and remains a major health problem. While optimal CDI testing remains unclear, current literature recommends testing patients whose symptoms are not clinically attributable to underlying conditions, e.g., laxatives. At Moffitt Cancer Center, a soft-stop alert was implemented to alert the provider if the patient received a laxative within the previous 48 hours of CDI testing. We aim to evaluate the incidence of CDI rates with prior laxative use in immunocompromised patients, as well as, the impact of the soft-stop alert in reducing CDI testing. METHODS: Retrospective, single-center, review of adult patients who were tested for CDI after the implementation of the soft-stop alert from October 1, 2020 to December 21, 2020. These patients were compared to a historical cohort of patients who were tested for CDI prior to the alert implementation from October 1, 2019 to December 31, 2019. The primary outcome was the percent of patients that received a laxative within 48 hours of CDI testing pre-alert compared to post-alert. Secondary outcomes included the percent of colonization versus active infection in this immunocompromised population, number and type of laxatives administered prior to testing, and the frequency of alert and reduction of CDI tests ordered. A cost-benefit analysis was also performed. RESULTS: In the historical cohort (n=480), 14.8% received a laxative within 48 hours of CDI testing (Figure 1). Within patients who received a laxative in this group, 4.2% had a definitive active infection. After the alert was implemented, a total of 630 CDI tests were ordered from October 1, 2020 to December 31, 2020, and the alert was fired for 123 (19.5%) tests ordered (Figure 2). Of the tests where the alert was fired, the CDI test was removed for 42.3% and continued for 57.7% of orders resulting in savings of &3,263. In this cohort, 5.6% of patients had a definitive active CDI infection who received a laxative and testing was continued (Figure 3). [Image: see text] Figure 2: CDI Test and Laxative Administration Alert [Image: see text] Figure 3: Post-Alert Laxatives Administered and CDI Test Result [Image: see text] CONCLUSION: The soft-stop alert implemented reduced CDI testing in patients who received a laxative in the last 48 hours correlating with a financial benefit, improvement in guideline adherence, and reduction in laboratory labor. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8644424
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86444242021-12-06 755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults Al-Bahou, Amanda Quilitz, Rod Pasikhova, Yanina Greene, John Open Forum Infect Dis Poster Abstracts BACKGROUND: Clostridioides difficile infection (CDI) rates have plateaued at historical highs in the United States since 2010 and remains a major health problem. While optimal CDI testing remains unclear, current literature recommends testing patients whose symptoms are not clinically attributable to underlying conditions, e.g., laxatives. At Moffitt Cancer Center, a soft-stop alert was implemented to alert the provider if the patient received a laxative within the previous 48 hours of CDI testing. We aim to evaluate the incidence of CDI rates with prior laxative use in immunocompromised patients, as well as, the impact of the soft-stop alert in reducing CDI testing. METHODS: Retrospective, single-center, review of adult patients who were tested for CDI after the implementation of the soft-stop alert from October 1, 2020 to December 21, 2020. These patients were compared to a historical cohort of patients who were tested for CDI prior to the alert implementation from October 1, 2019 to December 31, 2019. The primary outcome was the percent of patients that received a laxative within 48 hours of CDI testing pre-alert compared to post-alert. Secondary outcomes included the percent of colonization versus active infection in this immunocompromised population, number and type of laxatives administered prior to testing, and the frequency of alert and reduction of CDI tests ordered. A cost-benefit analysis was also performed. RESULTS: In the historical cohort (n=480), 14.8% received a laxative within 48 hours of CDI testing (Figure 1). Within patients who received a laxative in this group, 4.2% had a definitive active infection. After the alert was implemented, a total of 630 CDI tests were ordered from October 1, 2020 to December 31, 2020, and the alert was fired for 123 (19.5%) tests ordered (Figure 2). Of the tests where the alert was fired, the CDI test was removed for 42.3% and continued for 57.7% of orders resulting in savings of &3,263. In this cohort, 5.6% of patients had a definitive active CDI infection who received a laxative and testing was continued (Figure 3). [Image: see text] Figure 2: CDI Test and Laxative Administration Alert [Image: see text] Figure 3: Post-Alert Laxatives Administered and CDI Test Result [Image: see text] CONCLUSION: The soft-stop alert implemented reduced CDI testing in patients who received a laxative in the last 48 hours correlating with a financial benefit, improvement in guideline adherence, and reduction in laboratory labor. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8644424/ http://dx.doi.org/10.1093/ofid/ofab466.952 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Al-Bahou, Amanda
Quilitz, Rod
Pasikhova, Yanina
Greene, John
755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
title 755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
title_full 755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
title_fullStr 755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
title_full_unstemmed 755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
title_short 755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
title_sort 755. clostridioides difficile testing and the use of laxatives in immunocompromised adults
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644424/
http://dx.doi.org/10.1093/ofid/ofab466.952
work_keys_str_mv AT albahouamanda 755clostridioidesdifficiletestingandtheuseoflaxativesinimmunocompromisedadults
AT quilitzrod 755clostridioidesdifficiletestingandtheuseoflaxativesinimmunocompromisedadults
AT pasikhovayanina 755clostridioidesdifficiletestingandtheuseoflaxativesinimmunocompromisedadults
AT greenejohn 755clostridioidesdifficiletestingandtheuseoflaxativesinimmunocompromisedadults